Acute Myeloid Leukemia Real World Treatment Patterns

Pfizer

Status: Withdrawn

Conditions: Leukemia, Myeloid, Acute

Treatments: Drug: azacitidine; Drug: glasdegib; Drug: venetoclax

Study type: Observational

Funder types: Industry

Identifiers

NCT04230564

B1371038

Details and patient eligibility

About

Among patients with a diagnosis of AML who received non-intensive chemotherapy:

• Describe patient demographic and clinical characteristics
• Describe treatment patterns
• Describe effectiveness outcomes
• Evaluate tumor response

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. Confirmed diagnosis of AML on or after 01 January 2012 through Clinical Research Nurse (CRN) review of provider documentation of AML diagnosis in the medical record.

2. Receipt of non-intensive therapy at any point during first line therapy following initial AML diagnosis. For this study, non-intensive therapy will be defined as 1 of the following agents, alone or in combination with any other agent:

   1. AZA
   2. GLAS
   3. VEN

3. Age ≥18 years at initial diagnosis of AML.

Exclusion criteria

Patients meeting any of the following criteria will not be included in the study:

1. Record of 1 or more of the following confounding diagnoses at any point before or after AML diagnosis: Acute lymphoblastic leukemia; acute promyelocytic leukemia, aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; dermatofibrosarcoma protuberans; gastrointestinal stromal tumors.

Trial design

0 participants in 1 patient group

AML

Description:

Patients diagnosed with AML

Treatment:

Drug: venetoclax

Drug: glasdegib

Drug: azacitidine